Katy White

632 total citations · 1 hit paper
14 papers, 430 citations indexed

About

Katy White is a scholar working on Immunology, Rheumatology and Ophthalmology. According to data from OpenAlex, Katy White has authored 14 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Rheumatology and 4 papers in Ophthalmology. Recurrent topics in Katy White's work include Psoriasis: Treatment and Pathogenesis (8 papers), Spondyloarthritis Studies and Treatments (6 papers) and Ocular Diseases and Behçet’s Syndrome (4 papers). Katy White is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Spondyloarthritis Studies and Treatments (6 papers) and Ocular Diseases and Behçet’s Syndrome (4 papers). Katy White collaborates with scholars based in United States, United Kingdom and Germany. Katy White's co-authors include Andrew Blauvelt, John H. Greist, S. Rasmussen, G Chouinard, Veerle Vanvoorden, Kristian Reich, Christopher L. Cioffi, Andreas Pinter, Cynthia Madden and Ronald Vender and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Katy White

13 papers receiving 403 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Kenneth B. Gordon, Peter Foley et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katy White United States	6	192	173	102	92	66	14	430
Saifuddin Kharawala United States	8	85 0.4×	27 0.2×	67 0.7×	24 0.3×	29 0.4×	13	225
T. Nurminen Germany	9	194 1.0×	186 1.1×	10 0.1×	11 0.1×	13 0.2×	25	644
D. Camaioni Italy	6	48 0.3×	79 0.5×	147 1.4×	21 0.2×	3 0.0×	7	343
David Hägg Sweden	9	231 1.2×	10 0.1×	120 1.2×	34 0.4×	5 0.1×	17	441
D Golan United States	7	158 0.8×	37 0.2×	10 0.1×	27 0.3×	15 0.2×	13	347
Mingji Yi China	12	38 0.2×	134 0.8×	6 0.1×	15 0.2×	130 2.0×	42	443
Roland S. Medansky United States	9	71 0.4×	52 0.3×	184 1.8×	7 0.1×	14 0.2×	15	313
Bruce Solitar United States	6	35 0.2×	32 0.2×	5 0.0×	10 0.1×	59 0.9×	7	391
M Brush United States	6	37 0.2×	9 0.1×	8 0.1×	10 0.1×	31 0.5×	6	294
Shōichi Watanabe Japan	11	24 0.1×	15 0.1×	53 0.5×	7 0.1×	17 0.3×	35	304

Countries citing papers authored by Katy White

Since Specialization

Citations

This map shows the geographic impact of Katy White's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katy White with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katy White more than expected).

Fields of papers citing papers by Katy White

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katy White. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katy White. The network helps show where Katy White may publish in the future.

Co-authorship network of co-authors of Katy White

This figure shows the co-authorship network connecting the top 25 collaborators of Katy White. A scholar is included among the top collaborators of Katy White based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katy White. Katy White is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Warren, Richard B., Mark Lebwohl, Diamant Thaçi, et al.. (2025). Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal of Dermatology. 193(1). 44–55. 3 indexed citations

Horst‐Bruinsma, Irene van der, Matthew Brown, F. van Gaalen, et al.. (2025). POS0773 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS. Annals of the Rheumatic Diseases. 84. 933–934. 1 indexed citations

Mease, Philip J., Denis Poddubnyy, Rajan Bajracharya, et al.. (2025). P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies. Lara D. Veeken. 64(Supplement_3). 1 indexed citations

Mease, Philip J., Lianne S. Gensler, Ana‐Maria Orbai, et al.. (2025). Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 11(2). e005026–e005026.

Brown, Matthew A., Martín Rudwaleit, F. van Gaalen, et al.. (2024). Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases. 83(12). 1722–1730. 11 indexed citations

Rudwaleit, Martín, Matthew Brown, Nigil Haroon, et al.. (2024). P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Rudwaleit, Martín, Matthew A. Brown, F. van Gaalen, et al.. (2023). POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS. 614.2–615. 2 indexed citations

Poddubnyy, Denis, Lianne S. Gensler, Philip J. Mease, et al.. (2023). AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 1686–1687. 1 indexed citations

Strober, Bruce, C. Paul, Andrew Blauvelt, et al.. (2023). Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology. 89(3). 486–495. 28 indexed citations

10.

Blauvelt, Andrew, Jashin J. Wu, Kristian Reich, et al.. (2021). 27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial. Journal of the American Academy of Dermatology. 85(3). AB139–AB139. 6 indexed citations

11.

Gordon, Kenneth B., Peter Foley, James G. Krueger, et al.. (2021). Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 397(10273). 475–486. 170 indexed citations breakdown →

12.

Blauvelt, Andrew, Lars Iversen, Sandy McBride, et al.. (2021). Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. SKIN The Journal of Cutaneous Medicine. 5(6). s53–s53. 1 indexed citations

13.

Greist, John H., James W. Jefferson, Kenneth A. Kobak, et al.. (1995). A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology. 10(2). 57–66. 97 indexed citations

14.

Chouinard, G, Wayne K. Goodman, John H. Greist, et al.. (1990). Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.. PubMed. 26(3). 279–84. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact